Cases & Deals

  • Home
  • Practices
  • Avanir licenses D-DM from Concert for neurological disorders

Share

Avanir licenses D-DM from Concert for neurological disorders

February 2012

Client(s) Avanir Pharmaceuticals, Inc.

Jones Day represented Avanir Pharmaceuticals, Inc. in its worldwide, exclusive license from Concert Pharmaceuticals to develop and commercialize deuterium-modified dextromethorphan for the potential treatment of neurological and psychiatric disorders. Concert will receive upfront payment and is eligible to receive milestone payments and royalties.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.